TopStocks: Cadrenal Therapeutics Inc. (NASDAQ: CVKD)

Pipeline Expansion: Factor XIa and Frunexian

Cadrenal's acquisition of assets from eXIthera added significant depth to its anticoagulation pipeline. These assets include frunexian, a first in class IV Factor XIa inhibitor, and EP 7327, an oral Factor XIa inhibitor in development for major thrombotic indications.

Factor XIa has emerged as one of the most validated targets in cardiovascular drug development. It plays a limited role in normal clotting but a major role in pathological thrombosis. This makes FXIa inhibition a promising strategy for reducing clot formation while maintaining lower bleeding risk.

Large pharmaceutical companies have invested billions into this space, underscoring its long term commercial and scientific potential.

CVKD Potential Catalyst #2: Phase 2 Results Show Encouraging Reduction in Thrombotic Events

On February 24, 2026, Cadrenal Therapeutics announced results from a Phase 2 trial evaluating CAD-1005 in patients with heparin-induced thrombocytopenia (HIT). The randomized, blinded, placebo-controlled trial showed a greater than 25% absolute reduction in thrombotic events in the CAD-1005 treatment arm compared to placebo, with both groups receiving standard anticoagulant therapy.

This is the only blinded, placebo-controlled trial ever conducted in HIT.

The placebo group experienced a thrombotic event rate exceeding 75%, while the CAD-1005 group experienced a 50% event rate — demonstrating that adding a 12-LOX inhibitor to standard anticoagulants may be more effective than anticoagulants alone in preventing thrombotic events.

The study's primary endpoint was platelet count recovery rate, which the previous sponsor selected to validate a new surrogate endpoint. That primary endpoint was not met — platelet recovery rates were similar between both groups. However, Cadrenal notes that thrombotic events continued to occur even after platelet count recovery, suggesting platelet recovery is not an appropriate surrogate marker for clinical efficacy in HIT

The key secondary endpoint — incidence of new or worsening thrombotic events including radiologic progression — showed the encouraging reduction that supports further development.

The final dataset included 24 patients with presumptive HIT diagnosis, with primary analyses focused on 17 patients confirmed by central lab functional assay. All patients received concomitant standard anticoagulant therapy (argatroban or bivalirudin).

What This Means For Investors: This is the first clinical evidence in a controlled trial that directly targeting the immune mechanism driving HIT with a 12-LOX inhibitor can reduce thrombotic events beyond what standard anticoagulation alone achieves. The FDA has already granted the End-of-Phase 2 meeting, which means the regulatory path toward a pivotal Phase 3 registration trial is actively moving forward. Combined with Orphan Drug and Fast Track designations, CAD-1005 is now positioned as the most advanced first-in-class therapy targeting the root cause of HIT.

CVKD Potential Catalyst #3: Zacks Research Report Values CVKD at $25 Per Share

Zacks Small Cap Research published a report on Cadrenal Therapeutics on February 20, 2026, authored by analyst David Bautz, PhD. The firm incorporated VLX-1005 into its probability-adjusted discounted cash flow model and arrived at a $25 per share valuation — representing more than 300% upside from recent levels.

The analyst noted that VLX-1005 is expected to be the main focus for Cadrenal going forward, as it is ready for Phase 3 testing and directly targets the pathological drivers of HIT where few effective treatment options currently exist. The report confirmed that Cadrenal is planning an End-of-Phase 2 meeting with the FDA to discuss Phase 3 trial design, endpoints, and patient enrollment parameters.

Zacks modeled estimated costs for the Phase 3 program and projected share counts increasing to 5.0 million shares in 2026 and 7.0 million shares in 2027 as the company raises capital to fund development. Even with that dilution factored in, the valuation still lands at $25 per share. That speaks directly to the scale of the market opportunity the firm sees in VLX-1005 for HIT.

Zacks also reported that Cadrenal had approximately $3.9 million in cash as of September 30, 2025 with approximately 2.1 million shares outstanding and a fully diluted count of approximately 3.1 million when factoring in options and warrants.

Source: Zacks Small Cap Research Report

CVKD Potential Catalyst #4: CAD-1005 Acquisition Adds a First-in-Class HIT Treatment with FDA Designations

Cadrenal announced the acquisition of CAD-1005 (formerly VLX-1005) and related 12-lipoxygenase assets from Veralox Therapeutics. This acquisition immediately strengthens the pipeline with a late-stage,first-in-class drug candidate that has already secured both Orphan Drug Designation and Fast Track statusfrom the FDA, as well as orphan drug status from the European Medicines Agency.

CAD-1005 is a novel inhibitor of 12-LOX, targeting a key immune signaling pathway that drives Heparin-Induced Thrombocytopenia (HIT). HIT is a potentially life-threatening complication that can occur in patients exposed to heparin, the most widely used parenteral anticoagulant. According to the latest Zacks research, approximately 240,000 patients in the U.S. are screened annually for suspected HIT, with approximately 48,000 confirmed diagnoses each year.

The critical distinction here is that CAD-1005 does not simply thin the blood like existing HIT treatments. It targets the actual immune-driven platelet activation that causes the disease in the first place.

Current standard-of-care drugs like argatroban and bivalirudin only address coagulation downstream, leaving the core immune-mediated platelet activation unchecked. That means patients remain at persistent risk of thrombosis, bleeding, amputation, and death even while on treatment. There are currently zero approved therapies that target the immune-mediated platelet activation pathway in HIT. This is the gap CAD-1005 is designed to fill.

CAD-1005 works by selectively inhibiting 12-LOX, an enzyme that amplifies platelet activation through a lipid signaling molecule called 12-HETE. By blocking this amplification step, CAD-1005 targets the disease mechanism itself rather than just managing symptoms downstream.

Importantly, preclinical and clinical data show no increased bleeding signal with CAD-1005. This distinguishes it from every anticoagulant currently used to treat HIT, where bleeding complications are a major source of additional morbidity and mortality.

VLX-1005 Mechanism of Action — 12-LOX inhibition treats both platelet activation and thrombus formation in HIT.

Source: Cadrenal Therapeutics, Inc.

Clinical data across multiple studies:

Two Phase 1 studies in healthy volunteers demonstrated that CAD-1005 was well tolerated, with no deaths, no serious adverse events, and no trend in adverse event reporting with increasing doses. Pharmacokinetic data showed dose-linear increases, and a separate drug-drug interaction study with argatroban confirmed no evidence of interaction, which is critical because CAD-1005 is designed to be used alongside standard-of-care anticoagulation.

The Phase 2 proof-of-concept study (ALATHEA) evaluated CAD-1005 in patients with suspected HIT. Results announced on February 24, 2026 showed a greater than 25% absolute reduction in thrombotic eventsversus placebo. Cadrenal has been granted an End-of-Phase 2 meeting with the FDA scheduled for March 2026 to discuss Phase 3 registration trial design.

CAD-1005 Phase 2 Study Design — Proof-of-concept study complete, FDA engagement for Phase 3 planning underway.

Source: Cadrenal Therapeutics, Inc.

What This Means For Investors: Cadrenal acquired a Phase 2 asset addressing a condition with approximately 240,000 suspected cases and 48,000 confirmed cases annually in the U.S. alone according to Zacks research, within the $40 billion global anticoagulation market. There are currently zero approved therapies that target the immune-mediated platelet activation pathway in HIT, positioning CAD-1005 as a true first-in-class drug.

The regulatory designations accelerate the path forward. Orphan Drug Designation provides seven years of market exclusivity upon approval plus tax credits and reduced filing fees. Fast Track status enables more frequent FDA meetings,rolling review of the application, and potential priority review.

The deal structure is also investor-friendly. Veralox will receive milestone payments tied to clinical and regulatory achievements, plus royalties on future sales. This allows Cadrenal to preserve capital while advancing development, paying primarily as value is created.

CAD-1005 is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing. This is a novel mechanism with strong scientific rationale, positive human data, and regulatory support. Second-generation 12-LOX inhibitors are also being explored for type 1 diabetes and other immune-mediated diseases, suggesting meaningful platform expansion potential.

High Unmet Need in HIT — 240,000 suspected cases and 48,000 confirmed cases annually in the U.S. Current treatments cause or exacerbate bleeding risks.

Source: Cadrenal Therapeutics, Inc.

CVKD Potential Catalyst #6: A Major Acquisition Strengthening the Pipeline

Cadrenal's acquisition of eXIthera's portfolio significantly broadened its anticoagulation capabilities. With both a VKA and Factor XIa inhibitors under development, Cadrenal is now one of the only companies targeting the full spectrum of cardiovascular thrombotic risk.

CVKD Potential Catalyst #8: A High Level Board Appointment Strengthens Clinical Leadership

Cadrenal announced that Dr. Lee Scott Golden, M.D., has joined its Board of Directors as an independent member. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics and brings more than twenty five years of experience across rare disease, cardiovascular medicine, and late stage drug development.

His background includes senior roles at Pfizer, Actelion, Eisai, and multiple cardiovascular focused companies. Dr. Golden's expertise aligns directly with Cadrenal's development strategy, adding significant value as the company prepares for critical Phase 3 activities and regulatory interactions.

CVKD Potential Catalyst #9: Frunexian as the Only IV Small-Molecule FXIa Inhibitor Designed for Acute Hospital Use

Frunexian occupies a unique position in the Factor XIa landscape. While multiple major pharmaceutical companies all have FXIa programs in development, none of them are developing an intravenous small molecule designed for rapid on/off acute hospital use. Frunexian is the only one. With a short half-life of approximately 45 minutes, it can be turned on and off quickly during procedures, unlike IV monoclonal antibodies targeting FXI/FXIa which have half-lives measured in weeks. This gives Cadrenal a differentiated asset targeting a high-value niche in cardiopulmonary bypass, catheter thrombosis,and other device-associated settings where rapid-onset, rapid-offset anticoagulation is critical.